NFB42: A Protein with Therapeutic Potential (G26232)

Target Name: FBXO2

NCBI ID: G26232

FBXO2

NFB42: A Protein with Therapeutic Potential

Facebook is a social media platform that is widely used by people all over the world. It is part of the Facebook family of websites and apps, which also includes Instagram and WhatsApp. Facebook was founded in 2004 by Mark Zuckerberg and today has over 2.7 billion monthly active users worldwide. The company's mission is to give people a secure and private way to connect with each other.

NFB42 is a protein that is found in the nervous system of humans. It is a small molecule that plays a critical role in the function of the nervous system. NFB42 is made by the neural stem cells and is important for the development, maintenance, and repair of neural circuits.

NFB42 is also a drug target and has been shown to have a variety of therapeutic potential. One of the ways that NFB42 is being targeted is through its role in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's. Studies have shown thatNFB42 levels are significantly decreased in the brains of individuals with these diseases, which may contribute to the development and progression of the diseases.

Another way that NFB42 is being targeted is through its role in pain management. NFB42 has been shown to have pain-relieving properties and is being studied as a potential treatment for chronic pain. This is because NFB42 has been shown to reduce the activity of pain-sensitive neurons in the brain, which may help to reduce pain.

NFB42 is also being targeted as a potential treatment for other conditions, such as depression and anxiety. Studies have shown that NFB42 levels are lower in individuals with these conditions and thatNFB42 may have therapeutic potential in treating these conditions.

In addition to its potential therapeutic uses, NFB42 is also being studied as a potential biomarker for a variety of conditions. For example, studies have shown that NFB42 levels are often decreased in individuals with certain neurological conditions, such as Alzheimer's and Parkinson's. This may suggest that NFB42 could be a useful biomarker for these conditions.

Overall, NFB42 is a protein that is important for the development, maintenance, and repair of neural circuits. It is also being targeted as a potential drug target and biomarker for a variety of conditions, including neurodegenerative diseases, pain management, and depression and anxiety. While more research is needed, the potential therapeutic and diagnostic uses of NFB42 make it an important area of study.

Protein Name: F-box Protein 2

Functions: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Involved in the endoplasmic reticulum-associated degradation pathway (ERAD) for misfolded lumenal proteins by recognizing and binding sugar chains on unfolded glycoproteins that are retrotranslocated into the cytosol and promoting their ubiquitination and subsequent degradation. Prevents formation of cytosolic aggregates of unfolded glycoproteins that have been retrotranslocated into the cytosol. Able to recognize and bind denatured glycoproteins, preferentially those of the high-mannose type (By similarity)

The "FBXO2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets